FIELD: biochemistry.
SUBSTANCE: invention relates to a method for CD34+ population transduction of hematopoietic stem cells or progenitor cells, including culturing said cells in a culture medium in the presence of a lentiviral vector, an agent which enhances the transmission of prostaglandin EP receptor signals, and a poloxamer.
EFFECT: invention allows improving transduction efficiency of haematopoietic stem cells and precursor cells.
11 cl, 27 dwg, 32 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR GENE MODIFICATION OF HEMATOPOIETIC CELLS | 2019 |
|
RU2824194C2 |
| COMPOSITIONS AND METHODS FOR TREATING HAEMOGLOBINOPATHIES | 2015 |
|
RU2707540C2 |
| METHOD FOR STABLE CELL TRANSDUCTION BY VIRAL VECTORS | 2001 |
|
RU2280074C2 |
| TREATMENT OF CHRONIC GRANULOMATOUS DISEASE | 2020 |
|
RU2833487C1 |
| CHIMERIC ANTIGENIC RECEPTORS WITH MND-PROMOTER | 2015 |
|
RU2708311C2 |
| IMPROVED METHODS FOR PRODUCING ADOPTIVE CELL THERAPY AGENTS | 2015 |
|
RU2741899C2 |
| RECOMBINANT LENTIVIRAL VECTOR, HOST CELL TRANSDUCED WITH LENTIVIRAL VECTOR, METHODS FOR TRANSDUCTION AND USES THEREOF | 2002 |
|
RU2305708C2 |
| CHIMERIC ANTIGENIC RECEPTORS WITH MND PROMOTER | 2015 |
|
RU2799573C2 |
| DOUBLE VECTOR FOR SUPPRESSION OF HUMAN IMMUNODEFICIENCY VIRUS | 2010 |
|
RU2562868C2 |
| GENETIC CONSTRUCTS AND THEIR MIXTURES FOR ANTI-HIV THERAPY | 2017 |
|
RU2666991C1 |
